PCI Synthesis Wins Best NCE API Manufacturer in 2016

2016 saw more industry recognition and new lines of business

Posted: November 29, 2016

API Manufacturing and Pharmaceutical Manufacturing

2016-pci-marketing-brandingNewburyport, Mass. Nov, 2016 – PCI Synthesis, Inc., a drug substance Contract Manufacturing Organization (CMO) of new chemical entities (NCEs) and generic active pharmaceutical ingredients (APIs), announced that it won the 2016 Healthcare and Pharmaceutical Award for “Best NCE Manufacturer.”

Conducted by Global Health & Pharma (GHP), a global information sharing platform & a multi- disciplinary community of more than 260,000 readers, the Healthcare & Pharmaceuticals Awards seek to spotlight the talent and dedication of the individuals, departments and organizations that work tirelessly throughout the industry. GHP established “the awards (to) recognize all levels and all aspects of the healthcare and pharmaceutical sectors, choosing to focus not just on the obvious candidates – the practitioners and scientists at the cutting edge of these rapidly evolving industries – but also on the supporting cast … without whom many of the life-changing innovations and developments we see on an almost daily basis would simply not be possible.”

PCI Synthesis, which provides small and mid-sized companies with the expertise to manufacture complex small molecules to be used as APIs, offers three class 100,000 cGMP suites for pre-clinical and clinical manufacturing and 23 reactors with a total of 20,000 gallons of manufacturing capacity.

“This award, along with the eight CMO Leadership Awards that we’ve won over the past few years, continues to validate our approach,” said Edward S. Price, President of PCI Synthesis. “We spend a lot of time and money staying abreast of the latest technologies, processes, and FDA guidelines, but being named Best NCE Manufacturer is a tribute to our skilled and dedicated staff, who provide our emerging pharma customers with the expertise to manufacture complex small molecules as part of drug discovery and development.”

PCI Synthesis also announced the formation of its cGMP Advanced Polymer Development and Manufacturing Group, which is currently developing and manufacturing more than a dozen advanced polymer-based projects. As the largest independent cGMP-equipped CMO in New England, the company’s advanced polymer-based materials development and manufacturing capability significantly expands the company’s customer base and reach within this growing market.

Earlier this year, PCI Synthesis obtained registration and certification from the U.S. Drug Enforcement Administration (DEA) to handle Schedule II, III, IV and V controlled substances.

About PCI Synthesis

PCI Synthesis is a Pharmaceutical Development CMO (Contract Manufacturing Organization) based in Newburyport, MA and is the largest small molecule drug substance manufacturer in the New England area. PCI is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules.

To learn how PCI Synthesis can bring our capabilities as Best NCE API Manufacturer to help you get your project done on time and on budget, please call us at: (978) 462-5555.

Related posts:

SOCMA Welcomes New Members in Second Half of 2014
MassBio's First CRO/CMO Symposium on "Accelerating Drug Development" Met with Huge Success
PCI Synthesis obtains DEA registration for controlled substance development and manufacturing
Inc. Magazine Unveils 35th Annual List of America’s Fastest-Growing Private Companies—the Inc. 5000
PCI Synthesis picks up Life Science CMO Leaderships Awards in all six categories

About the Author

Ed Price CEO of PCI Synthesis
Ed is the President and CEO of PCI Synthesis (PCI), he serves as a co-chair of the New England CRO/CMO Council and sits on the Industrial Advisory Board for the Department of Chemical Engineering at UMass, Amherst. Ed is also a long standing member of the American Chemical Society and advises the Bulk Pharmaceutical Task Force of the Society of Chemical Manufacturer’s and Affiliates (SOCMA).

Do you have questions? Talk to Ed.